Shingina A, Puckrin R, Gulamhusein A

Language: English
References: 3
Page: 174-175
PDF size: 87.61 Kb.

Text Extraction

Dear editor:

Despite recommendations on the prevention of HBV reactivation in patients receiving immunosuppressive therapy, those treated with ≥ 4 weeks of corticosteroids remain at significant risk of HBV reactivation but are frequently overlooked. Here we describe the first two reported cases of HBV reactivation in the context of corticosteroid induced immunosuppression for treatment of IgG4-related disease.

REFERENCES

1. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-9.

2. Kim E, Voaklander R, Kasmin FE, Brown WH, Mannan R, Siegel JH. Autoimmune Pancreatitis: A Multiorgan Disease Presenting a Conundrum for Clinicians in the West. Gastroenterology & Hepatology 2015; 11: 606-11.

3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of agespecific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-9.